Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
PARIS, France, June 10, 2026 Sanofi announced that it will discontinue the Phase 3 MOBILIZE study evaluating riliprubart in...
PARIS, France, June 8, 2026 Sanofi announced that the European Commission has approved Sarclisa® (isatuximab) subcutaneous (SC) for the...
PARIS, France, May 28, 2026 Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
PARIS, France, May 18, 2026 Sanofi has announced positive Phase 2 ElevAATe trial results demonstrating that investigational therapy efdoralprin...
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Paris, France – April 22, 2026 In a landmark advancement for pediatric endocrinology, Sanofi has secured U.S. FDA approval...
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
PARIS, France, March 31, 2026 Sanofi has received European Commission approval for Rezurock® (belumosudil) for the treatment of chronic...
